Beaird Harris Wealth Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Beaird Harris Wealth Management’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24,400	Closed	-$4.64K	–	496
2023 Q2	$4.64K	Hold	24,400	–	–	﹤0.01%	326
2023 Q1	$8.3K	Hold	24,400	–	–	﹤0.01%	284
2022 Q4	$7.25K	Hold	24,400	–	–	﹤0.01%	366
2022 Q3	$10K	Hold	24,400	–	–	﹤0.01%	282
2022 Q2	$11K	Buy	+24,400	New	+$22.4K	﹤0.01%	244

Other funds holding NYMX

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

CAM

Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return

ODIJL

One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Beaird Harris Wealth Management's NYMX Position: Q3 2023 in Review

Beaird Harris Wealth Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 24,400 shares — an estimated $4.64K sold.

Beaird Harris Wealth Management first reported a position in NYMX in Q2 2022 and held it in 5 quarters. The position peaked at $11K in Q2 2022. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

Beaird Harris Wealth Management reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
Beaird Harris Wealth Management sold 24,400 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $4.64K.
Beaird Harris Wealth Management first reported a position in Nymox Pharmaceutical Corp in Q2 2022 and held it in 5 quarters.
Beaird Harris Wealth Management's Nymox Pharmaceutical Corp position peaked at $11K in Q2 2022.
5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Beaird Harris Wealth Management's 13F filing for Q3 2023, filed 15 Nov 2023.